Paired Deep Mutational Scanning of Lck Activity and Inhibitor Sensitivity Enables the Engineering of Pharmacological Control of T Cell Receptor Signaling
En palabras de los autores
Controlling signaling enzymes with small molecules is a central goal in chemical biology and is of great utility for engineering cell-derived immunotherapies. Yet strategies for conferring selective small-molecule sensitivity without disrupting a protein's native function remain limited. Here we present a generalizable approach to engineering small molecule-controlled multidomain protein kinases. Using deep mutational scanning of full-length Lck, a tyrosine kinase essential for T cell receptor (TCR) signaling, we measured the effect of nearly all single amino acid substitutions in the kinase domain on phosphotransferase activity. The resulting activity landscape defined the domain's tolerance to substitution, mapped the regulatory interfaces that tune phosphotransferase activity, and, by treating bulky substitutions as ligand proxies, nominated cryptic pockets where covalent liganding is predicted to allosterically inhibit Lck. In parallel screens, we measured the sensitization of each variant to five clinically approved, reversible drugs: dabrafenib, erlotinib, gefitinib, imatinib, and nilotinib. Together, these landscapes identified substitutions that preserved or enhanced activity while sensitizing Lck to inhibition. Sensitizing substitutions were distributed throughout the kinase domain, including positions more than 30 [A] from the ATP-binding site, implicating long-range allosteric networks linking distal perturbations to ATP-binding site conformation and inhibitor potency. Integrating the activity and sensitization landscapes yielded a nilotinib-sensitized variant, I312S, that supports TCR signaling and, upon drug treatment, selectively suppresses proximal signaling and IL-2 production in Jurkat cells even in the presence of endogenous Lck.
Apareció: jueves, 19 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.